ABCC4 and neoplasm: This is because CAB assesses the risk of recurrence by assessing the expression of the proteins (CD44, ABCC4, ABCC11, N-Cadherin, pan-Cadherin) involved in critical signaling pathways involved in the invasion of blood vessels by tumor cells leading to the spread, and drug resistance pathways; other than hormone signaling (ER, PR, and associated genes) and cell division/cell death (MDM2, MELK, PTTG1, etc. [35–38] and is thus less influenced by the clinical parameters and racial differences as well.